Clinical Trial Update: Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial update for vebreltinib as neoadjuvant therapy in MET exon 14 skipping mutant non-small cell lung cancer (Stage IIA-IIIB, N2); the study is not yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Vebreltinib (vebreltinib)

Snippet

Sponsor: Fudan University | Conditions: NSCLC, Neoadjuvant Therapy | Phase 2 | Status: NOT_YET_RECRUITING